Combination/multivalent mRNA vaccines
| Vaccine | Developer | Identifier | Phase | Main goal |
| COVID-19+influenza | ||||
| qIRV (22/23) bivalent BNT162b2 | Pfizer | NCT05596734 | 1/2 | To evaluate the safety and immunogenicity of modRNA quadrivalent influenza vaccine (qIRV (22/23)) and bivalent BNT162b2 (original/Omi BA.4/BA.5). |
| mRNA-1083.1 | Moderna | NCT05827926 | 1/2 | To evaluate the safety, reactogenicity and immunogenicity to determine mRNA-1083 (covid+influenza) vaccine composition and dose level. |
| mRNA-1083 | Moderna | NCT06097273 | 3 | To evaluate the safety and immunogenicity of mRNA-1083 (covid+influenza) vaccine as compared with active control, co-administered licensed influenza and COVID-19 vaccines. |
| RSV+influenza | ||||
| mRNA-1345 | Moderna | NCT06060457 | 3 | To evaluate the safety and immunogenicity of mRNA-1345 RSV vaccine when co-administered with a high dose (HD) quadrivalent seasonal influenza vaccine (Fluzone HD) in adults aged ≥65 years. |
| RSV+influenza+COVID-19 | ||||
| mRNA-1345 | Moderna | NCT05330975 | 3 | To evaluate the safety, and immunogenicity of mRNA-1345 RSV vaccine co-administered with a seasonal influenza vaccine (Afluria Quadrivalent) or mRNA-1273.214 (SARS-CoV-2). |
| mRNA-1010 mRNA-1045 mRNA-1230 mRNA-1273.214 mRNA-1345 | Moderna | NCT05585632 | 1 | To evaluate the safety and reactogenicity of multicomponent vaccines mRNA-1045 (influenza and RSV) and mRNA-1230 (influenza, RSV and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345 (RSV) and mRNA-1273.214 (SARS-CoV-2) vaccines. |
| COVID-19+influenza+RSV+CMV | ||||
| mRNA-1010 mRNA-1273 mRNA-1345 mRNA-1647 | Moderna | NCT05397223 | 1 | To evaluate the safety, reactogenicity and immunogenicity of vaccines. |
CMV, Cytomegalovirus; mRNA, messenger RNA; RSV, respiratory syncytial virus; VZV, varicella zoster virus.